Antioxidant Supplements and Breast Cancer: A Systematic Review and Meta-Analysis

Mohammad Moradi-Joo,1,2 Saeed Heidari,3 Maryam Seyed-Nezhad,2 Mohammad Esmaeil Akbari,1 Ahmad Moosavi,4 and Sayed Hossein Davoodi5,7

1Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
3Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
4Duzef University of Medical Sciences, Duzef, Iran
5Department of Clinical Nutrition and Dietology, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences, Food Science and Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Corresponding author: Sayed Hossein Davoodi, Department of Clinical Nutrition and Dietology, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences, Food Science and Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Tel/Fax: +98-2122748001, E-mail: hdavoodi1345@gmail.com

Received 2017 January 15; Revised 2017 December 23; Accepted 2018 March 05.

Abstract

Context: Breast cancer is the second most common type of cancer worldwide and the most frequent one among women. Some studies suggest a favorable role of antioxidants on breast cancer, but this is still controversial.

Objectives: The main objective of this article was to determine the safety and efficacy of antioxidant supplements on breast cancer.

Methods: In order to gather evidence, main databases (MEDLINE, PubMed, Cochrane Library, Science Direct, Trip, Google Scholar, Institute of Scientific Information (ISI), SCOPUS, and EMBASE) as well as relevant websites were searched without time limit up to November 2016. We searched with appropriate keywords and strategies. After the quality assessment of studies, study data were extracted by 2 reviewers. Because all the outcomes were dichotomous, relative risk by using the fixed-effects model proposed by Mantel-Hanzel was used in the meta-analysis. I2 values were used for the evaluation of heterogeneity. Analyses were conducted, using review manager and CMA Software.

Results: Out of 825 studies, 652 studies were entered firstly and 14 RCTs were selected after the final review. There was not significant difference between Antioxidant and Placebo group in breast cancer incidence (P = 0.88), quality of life (P = 0.79), daily hot-flash score (P = 0.87) and toxicity such as nausea-vomiting (P = 0.87), diarrhea (P = 0.17), constipation (P = 0.35), fatigue (P = 0.14), alopecia (P = 0.22), anemia (P = 0.67), headaches (P = 0.73), leukopenia (P = 0.2), and Neutropenia (P = 0.08).

Conclusions: The results of our meta-analysis do not support the effectiveness of antioxidants in reducing the risk of breast cancer. Also, this study showed that there is no sufficient clinical evidence to support the effectiveness of these supplements during the treatment of patients with breast cancer. It is recommended that clinician do not emphasize on these supplements in breast cancer treatment.

Keywords: Breast Cancer, Antioxidant, Vitamin, Supplement, Effectiveness, Meta-Analysis

1. Context

Breast cancer is one of the most common cancers among women. In other words, breast cancer ranked the first among all cancers after age 50 (1, 2). Generally, breast cancer is the third cause of death in European countries after lung and colorectal cancer and it annually causes more than half a million deaths in this continent (1, 3).

Over 508,000 women died in 2011 due to breast cancer worldwide. Although breast cancer is thought a disease of the developed world, almost 50% of patients with breast cancer and 58% of deaths occur in less developed countries. Incidence rates vary greatly worldwide from 19.3 per 100,000 women in Eastern Africa to 89.7 per 100,000 women in Western Europe. In most of the developing regions, the incidence rates are below 40 per 100,000. The lowest incidence rates are found in most African countries; but, here, breast cancer incidence rates are also increasing (4-7). The total number of patients with breast cancer in Iran is 40,000 and 7,000 new cases are added to this number annually (8).

Aging is considered as the most probable cause of cancer in female population. Family history and lifestyle are other variables that may affect the incidence of breast cancer in this population. Dietary habits, smoking, sedentary, weight gain, and obesity increase the risk of breast cancer (9, 10).
In recent years, the role of free radicals, which are also known as the reactive oxygen species in preventing a variety of diseases, has attracted researchers’ attention (11).

Previous epidemiological studies have investigated the association between the risk of cancer and the intake of fruits and vegetables rich in vitamins and antioxidants, and those findings are mixed (12, 13).

Many systematic reviews and meta-analyses have studied the relationship between antioxidants and their impacts on the prevention of various cancers, including colorectal cancer (14), skin cancer (15), endometrial cancer (16), esophageal cancer (17), gastrointestinal cancer (18), and other cancers (19-22). Greenlee (20) is the first one who systematically examined the role of antioxidants in breast cancer treatment; it is a qualitative study, which was conducted in New York in 2009.

Although there are many studies on the role of antioxidants in treatment of cancer, it seems that the effectiveness of these supplements is still unclear. Several studies have reported contradictory findings on the protective effects of these supplements on breast cancer. The only study that systematically examined these results (23) is somewhat old and has limitations including lack of using statistical quantitative methods. However, this study aimed at investigating the role of antioxidants in prevention of breast cancer and also the impact of these supplements on clinical outcomes of patients with breast cancer who are under treatment (chemotherapy, hormone therapy, etc.). The search for evidence was conducted without any time limitation until 2016. The data were analyzed, using meta-analysis method. It seems that this was the first meta-analysis conducted on safety and efficacy of antioxidants and vitamins in breast cancer. It is hoped that the results of this study help the evidence-based policy-taking and decision-making, using these supplements.

2. Methods

This systematic review and meta-analysis study is based on the Cochrane methodology for these types of studies (24).

The structured question for this review was as follows in Box 1:

**Box 1. Components of Structured Question**

| Components of Structured Question |
|-----------------------------------|
| - Population: women with or without breast cancer. |
| - Intervention: vitamin and antioxidant supplements. |
| - Comparator: placebo. |
| - Outcome: breast cancer incidence, adverse effects, quality of life, daily hot-flash score. |
| - Type of studies: randomized controlled trial. |

well as ‘and’ and ‘or’ between words of the same meaning and concept i.e. breast, cancer, antioxidant, supplement, and vitamin. The extracted articles were organized in Endnote software. After deleting the duplicate articles, 2 reviewers assessed the titles and abstracts of search results independently and selected potentially-relevant studies according to our main question (Box 1). The articles that were deemed to be irrelevant to the research objectives were excluded. Then, the full texts of the selected articles were gathered.

After collecting the articles full text, we reviewed their references. Those articles that did not possess the inclusion criteria were excluded.

Two separate and independent scholars investigated the articles inclusion criteria, and the differences between them were resolved by discussion or by the third scholar to reach a consensus, if required.

2.2. Selection Criteria of Articles

The main inclusion criteria were the following: 1, Studies that are designed as clinical trials; 2, involve women with or without breast cancer; 3, compare antioxidant supplement and placebo; 4, report breast cancer incidence, adverse effects, and/or quality of life outcomes of participant; and 5, are written in English language. The main exclusion criteria were the following: 1, basic or animal study; 2, review; 3, without relevant data; 4, trials with an unbalanced additional modality between groups; and 5, duplicate articles that have up-to-date versions available. Studies that were not published as full reports were not included.

2.3. Methodological Quality Appraisal

Two separate and independent scholars critically evaluated the quality of articles, and the differences between them were resolved by discussion or by the third scholar to reach a consensus, if required. Cochrane checklist for assessing the risk of bias was used for articles critical assessment. This tool evaluates the articles quality in 7 aspects as low, high, uncertain, and risk of bias (21). Seven mentioned
aspects are as follow: 1, random sequence generation; 2, allocation concealment; 3, masking of patients and personnel; 4, masking of outcome evaluation; 5, incomplete outcome data; 6, selective reporting bias; and 7, other risk of bias.

In general, if an article gains more than 70 scores, it will have a high quality. If the score is lower than 50, it will have a low quality. Finally, the scores between 50 and 70 have average quality.

2.4. Information Extraction

A special form was designed in Excel 2013 in order to extract the required data from papers at this stage. General information (Including first authors name, year of publication, journal publisher, and national or state of each article), information related to the paper content and structure (Such as study type, quality level, participants characteristics in each group and interventions description), information related to the outcome (Type of outcome, the dual-mode or continuous outcomes, and following outcomes), statistical information (Such as the sample size in each group, mean and standard deviation for continuous outcomes, the incidence rate in dual mode outcome, the confidence interval, and P value), and any other helpful information were recorded in this form.

We tried to contact the corresponding author when there were problems in some data extraction, especially statistical data.

2.5. Analysis Methods

In this study, the relative risk based on the Mantel-Haenszel method and Fix model were used to estimate the effect sizes of binary consequences. In this method, the relative risk was separately estimated in each study, using the number of events and sample size in each group. After weighing, estimated relative risks in each study were pooled by the Mantel-Haenszel statistical method, and 95% confidence interval for the total relative risk was estimated. The standardized mean difference (SMD), which is based on the inverse-variance method, was used for continuous outcomes.

Chi-square test and I2 statistic were used to investigate the data heterogeneity. If this statistic is greater than or equal to 45%, there will be heterogeneity (25, 26).

For all hypothesis tests, $P < 0.05$ was considered significantly different. Analyses were conducted, using RevMan version 5.1.3 (24) and comprehensive meta-analysis (CMA) Software.

3. Results

3.1. Study Selection and Characteristics of Included Studies

The initial search yielded 825 articles, of which 173 duplicated ones were deleted. Out of the 652 remaining papers, 619 ones were excluded based on the title and abstract. Studying the full report of the 33 remaining papers led to the inclusion of 14 RCT studies. Figure 1 demonstrates the search results and article selection.

Out of 14 analyzed RCTs, 6 articles (24-29) investigated the incidence of breast cancer in women without breast cancer diagnosis. In these 6 articles, the total number of women in Antioxidant group and Placebo group were 45,895 and 4,5981, respectively. The mean age of women was between 45 to 66 years and mean follow-up time varied between 4.1 and 12.6 years.

Other 8 RCT (30-37) investigated the clinical outcomes among women with breast cancer, who were receiving treatment. In 8 papers, the total number of women in Antioxidant group and Placebo group were 664 and 657, respectively. The age of women was between 18 and 81 years and follow-up time varied between 4 weeks and 36 months. All the including 15 studies were published between 1998 and 2016. The characteristics of the final articles are listed in Table 1.

3.2. Study Quality

The quality assessment of articles showed that out of 14 articles, 10 had an acceptable quality, 3 had moderate quality, and 1 had low quality (Figures 2).

3.2.1. Breast Cancer Incidence

Six studies (24-29) including 9 1876 women (45,895 Antioxidant and 4,5981 Placebo) assessed the breast cancer incidence. The overall Mantel-Hanzel Pooled RR calculated for breast cancer incidence was 0.99 (95% CI; 0.91, 1.08). This difference was not statistically significant ($P = 0.88$, Figure 3). Test for heterogeneity was not statistically significant ($I^2 = 0\%$, $P = 0.86$).

3.2.2. Quality of Life

Three RCTs (30, 34, 35) investigated the quality of life in patients with breast cancer. MacGregor and Bezerra used EORTC for measuring the quality of life and Glenn used Fact-B scale for this purpose. Due to different measurement tools in 3 studies, it was not possible to integrate them. Therefore, the studies conducted by MacGregor and Bezerra were integrated and the study of Glenn was separately reported. The mean and standard deviation for each
In Glenn’s trial, the Fact-B study was used to measure quality of life. The findings showed that the mean of quality of life at the 24th week in antioxidant group and placebo group was 111.9 (SD = 21.2) and 110.4 (SD = 22.1), respectively. The mean difference in these groups is 1.5; this difference is not statistically significant (CI: -4.03, 7.03; P = 0.6).

The Pooled SMD calculated for quality of life was 0.05 (95% CI: -0.32, 0.43). This difference was not statistically significant (P = 0.79, Figure 4). Test for heterogeneity was not statistically significant (I² = 0%).

Figure 1. Search results and article selection

TOTAL NUMBER OF ARTICLES FOUND: 825

 Articles screened on the basis of the title: 652

 Articles screened on the basis of the abstract: 132

 Articles screened on the basis of the full-text: 33

 Articles selected for Meta-Analysis: 14

Excluded articles: 173
Reason of the exclude:

- Duplicate articles

Excluded articles: 520
Reason of the exclude:

- Basic study or animal study
- No Antioxidant and vitamin
- No breast cancer

Excluded articles: 99
Reason of the exclude:

- Systematic Review and Meta-analysis
- No association between Antioxidant and breast cancer
- No full text

Excluded articles: 19
Reason of the exclude:

- No relevant data
- No comparation between Antioxidant and Placebo
- No RCT
- No English language

In Glenn’s trial, the Fact-B study was used to measure quality of life. The findings showed that the mean of quality of life at the 24th week in antioxidant group and placebo group was 111.9 (SD = 21.2) and 110.4 (SD = 22.1), respectively. The mean difference in these groups is 1.5; this difference is not statistically significant (CI: -4.03, 7.03; P = 0.6).
Table 1. Characteristics of the Final Articles

| Study   | Year | Study Type | Age, Y   | No. of Patients | Antioxidant Type | Mean Follow-up | Reference |
|---------|------|------------|----------|----------------|------------------|----------------|-----------|
| McGregor| 2005 | RCT        | Mean 64 (7-8) | Mean 64 (7-8) | 19,937          | 19,939         | 39876     | Vitamin E | 10.1 years | (24) |
| Lee     | 1999 | RCT        | 45 and older | 45 and older | 19,939          | 19,937         | 39876     | β-Carotene| 7 years    | (25) |
| HoPE Trial | 2005 | RCT        | Mean 64 (7)    | Mean 64 (7)    | 1,063           | 1,262          | 2545      | Vitamin E | 7 years    | (24) |
| Hercberg| 2004 | RCT        | Mean 61.4 (6.6) | Mean 61.4 (6.6) | 3,444          | 3,489          | 753       | Mixed     | 7.5 years  | (27) |
| Diallo  | 2016 | RCT        | Mean 61.4 (6.6) | Mean 61.4 (6.6) | 750            | 797            | 1548      | Iron intake| 12.6 years | (28) |
| Dufield | 2002 | RCT        | Mean 63 (9.9)  | Mean 63 (9.9)  | 181            | 167            | 348       | Selenium  | 6.4 years  | (29) |
| Bezerra | 2007 | RCT        | Mean 63 (6.6)  | Mean 63 (6.6)  | 19             | 16             | 35        | Centrum Silver | 4 Weeks | (30) |
| Cheri   | 2002 | RCT        | Mean 63 (6.6)  | Mean 63 (6.6)  | 59             | 66             | 123       | Oral Soy  | 4 Weeks    | (31) |
| Debra   | 1998 | RCT        | Mean 62 (6.6)  | Mean 62 (6.6)  | 54             | 50             | 104       | Vitamin E | 4 weeks    | (32) |
| Douglas | 2002 | RCT        | Mean 63 (6.6)  | Mean 63 (6.6)  | 181            | 167            | 348       | Selenium  | 6.4 years  | (29) |
| Glenn   | 2003 | RCT        | Mean 63 (6.6)  | Mean 63 (6.6)  | 181            | 167            | 348       | Centrum Silver | 4 Weeks | (33) |
| Ilson   | 2005 | RCT        | Mean 63 (6.6)  | Mean 63 (6.6)  | 181            | 167            | 348       | Oral Soy  | 6 weeks    | (34) |
| Susan   | 2000 | RCT        | Mean 63 (6.6)  | Mean 63 (6.6)  | 181            | 167            | 348       | Centrum Silver | 6 weeks | (35) |

3.2.3. Daily Hot-Flash Score

Three studies (31, 32, 37) including 402 patients (200 Antioxidant and 202 Placebo) assessed the daily hot-flash score. The Pooled SMD calculated for Daily Hot-Flash Score was 0.01 (95% CI: -0.18, 0.2). This difference was not statistically significant (P = 0.87, Figure 5). Test for heterogeneity was not statistically significant (I^2 = 0%).

3.3. Toxicity

3.3.1. Nausea/Vomiting

Six studies (31-36) including 1497 patients (745 Antioxidant and 752 Placebo) assessed the toxicity-nausea/vomiting outcome. The overall Mantel-Hanzel Pooled RR calculated for nausea/vomiting was 0.98 (95% CI; 0.8, 1.21). This difference was not statistically significant (P = 0.87, Table 2). Test for heterogeneity was not statistically significant (I^2 = 7%, P = 0.37).

3.3.2. Diarrhea

Three studies (31, 34, 36) including 609 patients (305 Antioxidant and 304 Placebo) assessed the toxicity-diarrhea outcome. The overall Mantel-Hanzel Pooled RR calculated for diarrhea was 0.7 (95% CI; 0.42, 1.16). This difference was not statistically significant (P = 0.17, Table 2). Test for heterogeneity was not statistically significant (I^2 = 0%, P = 0.69).
3.3.3. Constipation

Three studies (31, 34, 35) including 427 patients (214 Antioxidant and 213 Placebo) assessed the toxicity-constipation outcome. The overall Mantel-Hanzel Pooled RR calculated for constipation was 1.67 (95% CI; 0.57, 4.95). This difference was not statistically significant (P =
Table 2. Analysis of the Toxicity

| Toxicity Type       | No Study | Participants | Statistical Method     | Effect Estimate (M-H, fixed, 95% CI) | P Value |
|---------------------|----------|--------------|------------------------|--------------------------------------|---------|
| Nausea/vomiting     | 6        | 1,497        | Risk ratio             | 0.98 (0.80, 1.21)                     | 0.87    |
| Diarrhea            | 3        | 609          | Risk ratio             | 0.70 (0.42, 1.16)                     | 0.17    |
| Constipation        | 3        | 427          | Risk ratio             | 1.67 (0.57, 4.95)                     | 0.35    |
| Fatigue             | 3        | 1,058        | Risk ratio             | 0.69 (0.42, 1.13)                     | 0.14    |
| Alopecia            | 2        | 870          | Risk ratio             | 0.87 (0.69, 1.09)                     | 0.22    |
| Anemia              | 2        | 446          | Risk ratio             | 0.83 (0.36, 1.91)                     | 0.67    |
| Headaches           | 2        | 269          | Risk ratio             | 1.11 (0.63, 1.96)                     | 0.73    |
| Leucopenia          | 3        | 1,106        | Risk ratio             | 0.68 (0.38, 1.22)                     | 0.2     |
| Neutropenia         | 2        | 856          | Risk ratio             | 2.46 (0.90, 6.76)                     | 0.08    |
| Anemia              | 2        | 870          | Risk ratio             | 0.41 (0.16, 0.99)                     | < 0.00001|
| Gastritis           | 2        | 373          | Risk ratio             | 0.27 (0.21, 0.65)                     | 0.0005  |

Test for heterogeneity was not statistically significant ($I^2 = 0\%$, $P = 0.71$).

### 3.3.4. Fatigue

Three studies (32-34) including 1,058 patients (532 Antioxidant and 526 Placebo) assessed the toxicity-fatigue outcome. The overall Mantel-Hanzel Pooled RR calculated for fatigue was $0.69$ (95% CI; 0.42, 1.13). This difference was not statistically significant ($P = 0.14$, Table 2). Test for heterogeneity was not statistically significant ($I^2 = 0\%$, $P = 0.68$).

### 3.3.5. Alopecia

Two studies (33, 36) including 870 patients (430 Antioxidant and 440 Placebo) assessed the toxicity-alopecia outcome. The overall Mantel-Hanzel Pooled RR calculated for alopecia was $0.87$ (95% CI; 0.69, 1.09). This difference was not statistically significant ($P = 0.22$, Table 2). Test for heterogeneity was not statistically significant ($I^2 = 0\%$, $P = 0.9$).

### 3.3.6. Anemia

Two studies (34, 36) including 486 patients (246 Antioxidant and 240 Placebo) assessed the toxicity-anemia outcome. The overall Mantel-Hanzel Pooled RR calculated for anemia was $0.83$ (95% CI; 0.36, 1.91). This difference was not statistically significant ($P = 0.67$, Table 2). Test for heterogeneity was not statistically significant ($I^2 = 0\%$, $P = 0.43$).

### 3.3.7. Headaches

Two studies (32, 35) including 269 patients (134 Antioxidant and 135 Placebo) assessed the toxicity-headaches outcome. The overall Mantel-Hanzel Pooled RR calculated for headaches was $1.11$ (95% CI; 0.63, 1.96). This difference was not statistically significant ($P = 0.73$, Table 2). Test for heterogeneity was not statistically significant ($I^2 = 33\%$, $P = 0.22$).

### 3.3.8. Leukopenia

Three studies (33, 34, 36) including 1,106 patients (552 Antioxidant and 554 Placebo) assessed the toxicity-leukopenia outcome. The overall Mantel-Hanzel Pooled RR calculated for leukopenia was $0.68$ (95% CI; 0.38, 1.22). This difference was not statistically significant ($P = 0.2$, Table 2). Test for heterogeneity was not statistically significant ($I^2 = 0\%$, $P = 0.65$).

### 3.3.9. Neutropenia

Two studies (33, 34) including 856 patients (428 Antioxidant and 428 Placebo) assessed the toxicity-neutropenia outcome. The overall Mantel-Hanzel Pooled RR calculated for neutropenia was $2.46$ (95% CI; 0.9, 6.76). This difference was not statistically significant ($P = 0.08$, Table 2). Test for heterogeneity was not statistically significant ($I^2 = 0\%$, $P = 0.51$).

### 3.3.10. Asthenia

Two studies (33, 36) including 870 patients (430 Antioxidant and 440 Placebo) assessed the toxicity-asthenia outcome. The overall Mantel-Hanzel Pooled RR calculated for asthenia was $0.43$ (95% CI; 0.31, 0.59). This difference was statistically significant favors Antioxidant ($P < 0.00001$, Table 2). Test for heterogeneity was not statistically significant ($I^2 = 0\%$, $P = 0.53$).

### 3.3.11. Gastritis

Two studies (34, 36) including 373 patients (183 Antioxidant and 190 Placebo) assessed the toxicity-gastritis outcome. The overall Mantel-Hanzel Pooled RR calculated for gastritis was $0.37$ (95% CI; 0.21, 0.65). This difference was not statistically significant ($P = 0.0005$).

Test for heterogeneity was not statistically significant ($I^2 = 0\%$, $P = 0.71$).
come. The overall Mantel-Hanzel Pooled RR calculated for gastritis was 0.37 (95% CI; 0.21, 0.65). This difference was statistically significant and favored Antioxidant (P = 0.0005, Table 2). Test for heterogeneity was not statistically significant (I² = 57%, P = 0.13).

3.4. Publication Bias

In this study, 6 studies of breast cancer risk and 3 studies of side effects of women with breast cancer undergoing treatment have been investigated. Therefore, the publication bias in these groups of articles was separately evaluated. As shown in Figures 6 and 7, there is no significant difference, indicating the existence of the publication bias in the funnel plot of these two groups of articles and their distribution is almost symmetric.

4. Discussion

Firstly, this study aimed at investigating the preventive role of antioxidants and vitamins in the incidence of breast cancer; in this regard, 6 RCT studies (24-29) were analyzed. Also, this study aimed at investigating the effectiveness of these supplements in women with breast cancer, who were receiving various treatments such as chemotherapy, hormone therapy, and radiotherapy; in this regard, 8 RCT studies (30-37) were analyzed. In all the 14 papers, the antioxidants were investigated compared with placebo. The qualities of these 14 articles were evaluated based on Cochrane’s risk of bias criteria. It was shown that 13 articles had acceptable quality; only 1 article had low quality.

In 6 articles, which examined the preventive role of antioxidants in the incidence of breast cancer, the role of vitamin E, beta-carotene, selenium, iron, and various types of vitamins, and antioxidants was examined in 2, 1, 1, 1, and 1 article, respectively. In this study, regardless of the used antioxidant type, 6 articles were integrated. The overall sample size in these articles was 91,876 participants; they were followed-up on average 4 to 12 years. The meta-analysis of these 6 articles showed that there was no statistically significant difference between people who used antioxidants and those who used placebo (P = 0.88). In addition, none of the 6 articles reported any significant difference between the two groups; all of the 6 articles showed that the antioxidants have no significant role in the prevention of breast cancer in studied population. In this analysis, no heterogeneity was seen (P = 0.86). Considering the relatively high sample size, lack of heterogeneity, and analysis of each of these articles, it seems that the antioxidants and vitamins have no sufficient role in preventing the breast cancer development.

The main objective of other 8 articles was evaluation of the clinical outcomes in women with breast cancer, who were receiving treatment (such as chemotherapy, radiotherapy, etc.) and used antioxidants and vitamins. The 10 articles were designed as a randomized trial. The antioxidants, which were used in 3 oral soy articles, included vitamin E in 1 article, melatonin in 1 article, zinc in 1 article, Safforis in 1 article, CoQ10 in 1 article, Centrum in 1 article, and Curcumin in 1 article.

Out of 8 articles, 3 RCTs (30, 34, 35) reviewed the quality of life. MacGregor and Bezerra used EORTC for measuring quality of life and Glenn used Fact-B scale for this purpose. Due to different measurement tools in 3 studies, it was not possible to integrate them. Therefore, the studies conducted by MacGregor and Bezerra were integrated and the study of Glenn was separately reported. The meta-analysis of MacGregor and Bezerra articles with a sample size of 107 patients showed that the outcome was not sig-
significant in patients in antioxidant and placebo groups (P = 0.79). On the other hand, Glenn's trial with a sample size of 236 patients and using Fact-B scale as a measure of quality of life showed that there was no significant difference between 2 groups (P = 0.6). Overall, the results of these 3 articles suggested that the antioxidants do not improve quality of life of patients with breast cancer, who receive chemotherapy, radiotherapy, and other treatments.

Considering the outcome of Daily Hot-Flash, the meta-analysis results of 3 articles (31, 32, 37) with a sample size of 402 patients showed that the outcome was not significant between 2 groups (P = 0.87). Considering the lack of heterogeneity between these articles, it seems that the antioxidants have no impact on improving the symptoms of Daily Hot-Flash outcome in patients with breast cancer.

The reduction of side effects was examined in 6 articles. The meta-analysis results showed that there was no significant difference between antioxidant and placebo groups in nausea-vomiting (P = 0.87), diarrhea (P = 0.47), constipation (P = 0.35), fatigue (P = 0.14), alopecia (P = 0.22), anemia (P = 0.67), headaches (P = 0.73), leukopenia (P = 0.2), and Neutropenia (P = 0.08), except in gastritis and asthenia.

This study had several limitations. Since the findings of this study were based on interventions articles, which examined the role of antioxidants and since the biological activities of supplements are probably different from vegetables and fruits, it is believed that these results cannot be generalized to the role of fruits and vegetables. In examining the preventive role of fruits and vegetables, the observation studies, including treatment-control studies or cohort studies may be used. On the other hand, given that from 6 studies, which were conducted to examine the preventive role of antioxidants, only 2 studies were conducted in healthy female population and other articles were conducted on women at risk or with a history of cancer, the generalization of these results to healthy population should be done with caution.

In 8 RCT studies examining the impact of antioxidants on patients with breast cancer, only the quality of life, daily hot-flash, and toxicity results were common; there was no community in other results in studies. This study aimed at conducting quantitative meta-analysis of outcomes; for this reason, this study did not qualitatively assess other outcomes of these papers. In addition to these 8 articles, other studies were excluded due to lack of criteria and the desired outcome. Another limitation of this study was the short follow-up duration of outcomes in 8 articles, which examined the role of antioxidant in women with breast cancer who were receiving treatment.

Unfortunately, we have just entered studies that were published in English and Persian due to limited time and resources. But, blinding method was used in selection and quality evaluation stages in order to avoid referral bias.

It seems that a systematic review and synthesis of qualitative studies on the role of antioxidants in women with breast cancer is essential to achieve better and more logical conclusions. On the other hand, due to lack of strong and visible evidence to support antioxidants usage, it is recommended that the clinicians prescribe these supplements cautiously, especially in patients with breast cancer who are receiving treatment.

4.1. Conclusions

The current meta-analysis of randomized controlled trials suggests that there is no clinical evidence to support the efficacy of vitamin and antioxidant supplements in reducing the risk or preventive effect of breast cancer. The evidence is currently insufficient to inform clinician and patient guidelines on the use of antioxidant supplements during the breast cancer treatment. The potential effects (either beneficial or detrimental) of antioxidant supplements on human health, particularly in relation to breast cancer, should not be overemphasized. The findings and explanations presented in this study should be explored in future research. Thus, well designed clinical trials and observational studies are needed to determine the short- and long-term effects of such agents.

Acknowledgments

The authors would like to thank the following individuals who have contributed at various stages through the development of this project.

Footnotes

Authors’ Contribution: None declared.
Conflict of Interests: The authors have no conflict of interests relevant to this article to disclose. All authors declare that no benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
Financial Disclosure: None.
Funding/Support: This study was supported by Cancer Research Center, Shahid Beheshti University of Medical Science.
Role of the Sponsor: None.

References

1. Boyle P, Levin B. World Cancer Report 2008 (Internet Monography). 2008, [cited 22 Jul]. Available from: http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/wcr_2008.pdf.
1. Lippman M, de Muna C. Harrison Principios de Medicina Interna (Internet Monography). Columbus: McGraw Hill Medical; 2009, [cited 22 Jul]. Available from: http://www.harrisonmedicine.com/content.aspx?Id=7716746&searchStr=cor-rectoloral.

2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18(7):1261-73. doi: 10.1093/annonc/mdm166. [PubMed: 17282443].

3. Coleman MP, Quaresma M, Berrino F, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet 2008;371(9605):204-11. doi: 10.1016/S0140-6736(08)60266-6. [PubMed: 18039491].

4. Anderson BO, Yip CH, Smith RA, Eniu A, Sener SF, Shyyan R, et al. Clinical practice guidelines: management of early breast cancer. J Natl Cancer Inst 2008;100(10):711-41. doi: 10.1093/jnci/djn007. [PubMed: 18481143].

5. Coleman MP, Quaresma M, Berrino F, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet 2008;371(9605):204-11. doi: 10.1016/S0140-6736(08)60266-6. [PubMed: 18481143].

6. Anderson BO, Yip CH, Smith RA, Eniu A, Sener SF, Shyyan R, et al. Clinical practice guidelines: management of early breast cancer. J Natl Cancer Inst 2008;100(10):711-41. doi: 10.1093/jnci/djn007. [PubMed: 18481143].

7. Anderson BO, Yip CH, Smith RA, Eniu A, Sener SF, Shyyan R, et al. Clinical practice guidelines: management of early breast cancer. J Natl Cancer Inst 2008;100(10):711-41. doi: 10.1093/jnci/djn007. [PubMed: 18481143].

8. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Nafisi K, et al. Breast cancer in Iran: an epidemiological review. Breast J 2007;13(4):383-91. doi: 10.1111/j.1524-4741.2007.00446.x. [PubMed: 17591043].

9. Steinmetz KA, Potter JD. Vegetables, fruit, and cancer. II. Mechanisms. Cancer Causes Control 1999;2(6):427-42. doi: 10.1023/A:1009905410409. [PubMed: 10505401].

10. Sander CS, Chang H, Hamf M, Elsner P, Thiele JJ. Role of oxidative stress and the antioxidant network in cutaneous carcinogenesis. Int J Dermatol 2004;43(5):326-35. doi: 10.1065/ijd5431.2004.022238. [PubMed: 15073561].

11. Peters JM, Thun MJ, Lee I, Heath CW Jr,中心人物 without author. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutrition Prevention of Cancer Clinical Trial. Cancer Epidemiol Biomarkers Prev 2004;13(11):1933-42. doi: 10.1158/1055-9965.EPI-04-0409. [PubMed: 15574472].

12. Bandera EV, Gifkins DM, Moore DF, McCullough ML, Kushi LH. Antioxidant Supplementation and Incidence of Cardiovascular Disease and Cancer: the Women's Health Study, a randomized controlled trial. JAMA 2005;294(1):56-65. doi: 10.1001/jama.294.1.56. [PubMed: 15998091].

13. Lee IM, Cook NR, Manson J, Buring JE, Hennekens CH. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study J Natl Cancer Inst 1999;91(24):2002-6. doi: 10.1093/jnci/91.24.2002. [PubMed: 10601038].

14. Lonn E, Bosch J, Yusuf S, Pogue J, Arnold JM, et al. Effects of long-term fish oil supplements on cardiovascular events and cancer: a randomized controlled trial. JAMA 2007;298(1):93-47. doi: 10.1001/jama.298.1.93. [PubMed: 17499671].

15. Hercberg S, Galan P, Preziosi P, Bertrais S, Menni L, Malvy D, et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004;164(2):2335-42. doi: 10.1001/archinte.164.2.2335. [PubMed: 15374125].

16. Bandera EV, Deschamps A, Partula V, Latino-Martel P, Srour B, Hercberg S, et al. Dietary iron intake and breast cancer risk: modulation by an antioxidant supplementation. Oncotarget 2016;7(48):79088-96. doi: 10.18632/oncotarget.12592. [PubMed: 27738321].

17. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combis G, Slate EH, Fischbach LA, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutrition Prevention of Cancer Clinical Trial. Cancer Epidemiol Biomarkers Prev 2004;13(11):1933-42. doi: 10.1158/1055-9965.EPI-04-0409. [PubMed: 15574472].

18. MacGregor CA, Canney PA, Patterson G, McDonald R, Paul J. A randomized, double-blind controlled trial of vitamin E for hot flashes in breast cancer patients receiving anthracycline-based chemotherapy. J Support Oncol 2007;5(6):347-52. doi: 10.1016/j.suponc.2007.03.003. [PubMed: 17587886].

19. Miller N, Miller H, Hill LT. The impact of antioxidant supplementation on clinical outcomes in the critically ill: A meta-analysis. Southern Afr J Crit Care 2013;19(2):18-26. doi: 10.7966/jaadc149. [PubMed: 20096293].

20. Greenlee H, Hershman DL, Jacobson JS. Use of antioxidant supplements during breast cancer treatment: a comprehensive review. Breast Cancer Res Treat 2009;115(3):437-52. doi: 10.1007/s10549-008-0919-0. [PubMed: 18839308].

21. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. The Cochrane Collaboration; 2017, [updated 2017]. Available from: http://www.cochrane-handbook.org.

22. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21(11):1539-58. doi: 10.1002/sim.1185. [PubMed: 1211919].

23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557. [PubMed: 12954528].

24. Lee IM, Cook NR, Gaziano JM, Gordon D, Baker PM, Manson J, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study, a randomized controlled trial. JAMA 2005;294(1):56-65. doi: 10.1001/jama.294.1.56. [PubMed: 15998091].

25. Lee IM, Cook NR, Manson J, Ewing JA, Hennekens CH. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study J Natl Cancer Inst 1999;91(24):2002-6. doi: 10.1093/jnci/91.24.2002. [PubMed: 10601038].

26. Lonn E, Bosch J, Yusuf S, Sheridan F, Pogue J, Arnold JM, et al. Effects of long-term fish oil supplements on cardiovascular events and cancer: a randomized controlled trial. JAMA 2007;298(1):93-47. doi: 10.1001/jama.298.1.93. [PubMed: 17499671].

27. Hercberg S, Galan P, Preziosi P, Bertrais S, Menni L, Malvy D, et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004;164(2):2335-42. doi: 10.1001/archinte.164.2.2335. [PubMed: 15574472].

28. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combis G, Slate EH, Fischbach LA, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutrition Prevention of Cancer Clinical Trial. Cancer Epidemiol Biomarkers Prev 2004;13(11):1933-42. doi: 10.1158/1055-9965.EPI-04-0409. [PubMed: 15574472].

29. MacGregor CA, Canney PA, Patterson G, McDonald R, Paul J. A randomized, double-blind controlled trial of oral soy supplements
versus placebo for treatment of menopausal symptoms in patients with early breast cancer. *Eur J Cancer*. 2005;41(5):708-14. doi: 10.1016/j.ejca.2005.01.005. [PubMed: 15763646].

36. Lissoni P, Barni S, Mandala M, Ardizzoia A, Paolorossi F, Vaghi M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. *Eur J Cancer*. 1999;35(12):1688-92. doi: 10.1016/S0959-8049(99)00159-8. [PubMed: 10674014].

37. Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, LaVasseur BL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. *J Clin Oncol*. 2000;18(5):1068-74. doi: 10.1200/JCO.2000.18.5.1068. [PubMed: 10694559].